Literature DB >> 22923182

Subsequent entry biologics/biosimilars: a viewpoint from Canada.

Anthony S Russell1, Vandana Ahluwalla, Cheryl Barnabe, Shahin Jamal, Robert C Offer, Wojciech P Olszynski, Kam Shojania, Boulos Haraoui.   

Abstract

We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22923182     DOI： 10.1007/s10067-012-2066-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  7 in total

Review 1.  Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.

Authors:  Wolfgang Jelkmann
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

2.  Hearing shines spotlight on biosimilar controversies.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Biosimilar peptides: need for pharmacovigilance.

Authors:  Shashank R Joshi
Journal:  J Assoc Physicians India       Date:  2011-04

4.  Biosimilars: the debate continues.

Authors:  Robert A Colbert; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2011-10

5.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  R A Rudick; N A Simonian; J A Alam; M Campion; J O Scaramucci; W Jones; M E Coats; D E Goodkin; B Weinstock-Guttman; R M Herndon; M K Mass; J R Richert; A M Salazar; F E Munschauer; D L Cookfair; J H Simon; L D Jacobs
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

6.  Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers.

Authors:  Namyi Gu; Sojeong Yi; Tae-Eun Kim; Jaewoo Kim; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu
Journal:  Clin Ther       Date:  2011-11-14       Impact factor: 3.393

Review 7.  A reappraisal of generic bisphosphonates in osteoporosis.

Authors:  J A Kanis; J-Y Reginster; J-M Kaufman; J-D Ringe; J D Adachi; M Hiligsmann; R Rizzoli; C Cooper
Journal:  Osteoporos Int       Date:  2011-09-28       Impact factor: 4.507
  7 in total
  3 in total

Review 1.  Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.

Authors:  Shane M Devlin; Brian Bressler; Charles N Bernstein; Richard N Fedorak; Alain Bitton; Harminder Singh; Brian G Feagan
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

2.  Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

Authors:  David Grabowski; Bradley Henderson; Dennis Lam; Edward C Keystone; Carter Thorne; Shahin Jamal; Janet Pope; Boulos Haraoui; Daming Lin; Leigh Revers
Journal:  Clin Rheumatol       Date:  2015-01-15       Impact factor: 2.980

3.  Effect on Patients' Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization.

Authors:  Jennifer Fenna; Micheal Guirguis; Caroline Ibrahim; Neeta Shirvaikar; Irwindeep Sandhu; Sunita Ghosh; Melissa Jenkins
Journal:  Can J Hosp Pharm       Date:  2021-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.